XML 17 R37.htm IDEA: XBRL DOCUMENT
v2.4.0.6

STOCKHOLDERS' EQUITY (Details) (USD $) | 0 Months Ended |  |  | 0 Months Ended | 12 Months Ended |  | 12 Months Ended |  | 12 Months Ended |  | 12 Months Ended |  | 12 Months Ended |  | 12 Months Ended |  | 12 Months Ended |  |  | 12 Months Ended |  | 12 Months Ended |  | 12 Months Ended
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Feb. 04, 2008 | Nov. 07, 2007 | Dec. 31, 2012 | Dec. 31, 2009 | Feb. 04, 2008 Warrants [Member] | Nov. 07, 2007 Warrants [Member] | Dec. 31, 2012 Warrants [Member] | Dec. 31, 2012 2012 Series B private placement [Member] | Dec. 31, 2012 2012 investor relations advisor [Member] | Dec. 31, 2011 2011 November Private Placement (1) [Member] | Dec. 31, 2012 2011 November Private Placement (1) [Member] | Dec. 31, 2011 2011 November Private Placement (1) [Member] Warrants [Member] | Dec. 31, 2012 2011 November Private Placement (1) [Member] Warrants [Member] | Dec. 31, 2012 2011 November Private Placement (1) [Member] Warrant2 [Member] | Dec. 31, 2012 2011 November Private Placement (2) [Member] | Dec. 31, 2012 2011 November Private Placement (2) [Member] Warrants [Member] | Dec. 31, 2011 2011 November Private Placement (2) [Member] Warrant2 [Member] | Dec. 31, 2012 2011 November Private Placement (2) [Member] Warrant2 [Member] | Dec. 31, 2012 2011 November Placement Agent Warrants [Member] | Dec. 31, 2012 2011 November Placement Agent Warrants [Member] Warrants [Member] | Dec. 31, 2012 2011 November Placement Agent Warrants [Member] Warrant2 [Member] | Dec. 31, 2012 2011 Investor Relations Advisor 1 [Member] | Dec. 31, 2012 2010 December Registered Direct Offering [Member] | Dec. 31, 2012 2010 January Registered Direct Offering [Member] | Dec. 31, 2012 2010 January Placement Agent Warrants [Member] | Dec. 31, 2010 2010 Investor Relations Advisor 2 [Member] | Dec. 31, 2012 2010 Investor Relations Advisor 2 [Member] | Dec. 31, 2012 2010 Investor Relations Advisor 3 [Member] | Dec. 31, 2012 2009 Investor Relations Advisor 4 [Member] | Dec. 31, 2010 2009 Business Consultant [Member] | Dec. 31, 2012 2009 Business Consultant [Member] | Dec. 31, 2009 2009 Business Consultant [Member] | Dec. 31, 2012 2008 Preferred Stock Offering [Member] | Dec. 31, 2011 2008 Preferred Stock Offering [Member] | Dec. 31, 2010 2008 Preferred Stock Offering [Member] | Dec. 31, 2009 2008 Preferred Stock Offering [Member] | Dec. 31, 2012 2008 Somanta Accounts Payable [Member] | Dec. 31, 2012 2008 Investor Relations Advisor 5 [Member] | Dec. 31, 2012 2008 Investor Relations Advisor 6 [Member] | Dec. 31, 2012 2007 Preferred Stock Offering [Member] | Dec. 31, 2011 2007 Preferred Stock Offering [Member] | Dec. 31, 2010 2007 Preferred Stock Offering [Member] | Dec. 31, 2009 2007 Preferred Stock Offering [Member] | Dec. 31, 2012 2006 Convertible Note 1 [Member] | Dec. 31, 2012 2006 Convertible Note 2 [Member] | Dec. 31, 2012 2006 Convertible Note 3 [Member] | Dec. 31, 2012 2006 Convertible Notes [Member] | Dec. 31, 2012 2006 Convertible Notes [Member] Warrants [Member] | Dec. 31, 2012 2011 Private Placement Offering - New Common Stock and Warrants [Member] | Dec. 31, 2011 2011 Private Placement Offering - New Common Stock and Warrants [Member]
Class of Warrant or Right [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants Outstanding (in shares) |  |  | 35,733,943 |  |  |  |  | 20,000,000 | [1] | 30,000 | [2] |  | 2,144,656 | [3] |  | 1,857,156 | 287,500 | 2,144,656 | [3] | 1,857,156 |  | 287,500 | 36,893 | [3] | 18,447 | 18,446 |  | 12,500 | [4] | 930,664 | [5] | 1,041,432 | [6] | 125,109 | [6] |  | 60,000 | [7] | 55,000 | [8] | 25,000 | [9] |  | 60,000 | [10] |  | 499,584 | [11] |  |  |  | 246,753 | [12] | 50,000 | [13] | 40,000 | [14] | 3,649,880 | [15] |  |  |  | 3,818,180 | [16] | 386,364 | [16] | 377,272 | [16] | 4,581,816 |  |  |
Exercise Price (in dollars per share) |  |  |  | $ 3.50 |  |  |  | $ 0.50 | [1] | $ 1.77 | [2] |  | $ 1.67 | [3] |  |  |  | $ 2.00 | [3] |  |  |  |  |  |  | $ 2.00 | [3] | $ 2.30 | [4] | $ 3.06 | [5] | $ 3.00 | [6] | $ 3.75 | [6] |  | $ 2.16 | [7] | $ 2.63 | [8] | $ 3.50 | [9] |  | $ 2.07 | [10] |  | $ 0.50 | [11] |  |  |  | $ 3.50 | [12] | $ 3.15 | [13] | $ 3.00 | [14] | $ 0.50 | [15] |  |  | $ 3.50 | $ 1.32 | [16] | $ 1.32 | [16] | $ 1.32 | [16] |  |  |  |
Expiration Date |  |  |  |  |  |  |  |  |  |  |  |  | 2010/05&2014/30 | [3] |  |  |  | 11/2010 & 30/2016 | [3] |  |  |  | 11/2010 & 30/2016 | [3] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Expiration Date |  |  |  |  |  |  |  | Oct. 24, 2018 | [1] | Apr. 19, 2014 | [2] |  | May 10, 2014 |  |  |  |  | Nov. 10, 2016 |  |  |  |  | Nov. 10, 2016 |  |  |  |  | Apr. 15, 2014 | [4] | Dec. 14, 2015 | [5] | Jan. 26, 2015 | [6] | Jan. 26, 2015 | [6] |  | Oct. 01, 2013 | [7] | Oct. 14, 2013 | [8] | Nov. 04, 2014 | [9] |  | Jul. 23, 2014 | [10] |  | Feb. 24, 2014 | [11] |  |  |  | Jan. 04, 2014 | [12] | Jan. 03, 2013 | [13] | Sep. 01, 2013 | [14] | Nov. 10, 2013 | [15] |  |  |  | Feb. 16, 2015 | [16] | Oct. 24, 2015 | [16] | Dec. 06, 2015 | [16] |  |  |  |
Exercisable period of warrants | 6 years | 6 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 6 years |  |  |  |  |  |  |  |  |  |  | 6 years |  | 5 years |
Investor relations consulting services expense |  |  |  |  |  |  |  |  |  | $ 10,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 17,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair value of warrants (in dollars per share) | $ 2.29 | $ 2.59 | $ 3.50 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 2.29 |  |  |  |  |  |  |  |  |  |  | $ 2.50 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Expected dividend yield (in hundredths) |  |  |  |  | 0.00% | 0.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0.00% |  |  |  |  |  |  |  |  |  |  | 0.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |
Risk-free interest rate (in hundredths) |  |  |  |  | 2.75% | 3.84% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2.75% |  |  |  |  |  |  |  |  |  |  | 3.84% |  |  |  |  |  |  |  |  |  |  |  |  |  |
Expected volatility rate (in hundredths) |  |  |  |  | 110.00% | 110.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 110.00% |  |  |  |  |  |  |  |  |  |  | 114.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |
Expected term |  |  |  |  | 6 years | 6 years | 6 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 6 years |  |  |  |  |  |  |  |  |  |  | 6 years |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants received by investor relation advisor to purchase common stock (in shares) |  |  | 3,895,047 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 194,000 |  |  |  |  |  |  |  |  |  | 150,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants expired (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 134,000 |  |  |  |  |  |  | 90,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Decreased exercise price of warrants (in dollars per share) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 0.50 |  | $ 1.45 | $ 2.55 | $ 3.00 |  |  |  |  |  |  | $ 0.50 |  | $ 1.45 | $ 2.55 | $ 3.00 |  |  |  |  |  |  |  |  |  |
Purchase price of Somanta Pharmaceuticals Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,576,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of common shares issued in acquisition (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 538,508 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants extended exercisable period |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3 years |  |
Sale of shares of common stock (in shares) |  |  |  |  |  |  |  |  |  |  |  | 4,289,312 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants to acquire shares of common stock (in shares) |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2,144,656 |  |  |  |  |  | 2,144,656 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate purchase price of common stock and warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 6,200,000
Proceeds, net of cash issuance costs from the sale |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 5,800,000
Issuance of warrants for placement agent fees (in shares) | 45,417 | 209,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 18,447 | 18,446 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
[1] | In connection with a private placement offering on October 25, 2012, warrants to purchase 20,000,000 shares of common stock at $0.50 per share were issued. All of the warrants are exercisable immediately and expire on October 24, 2018.
[2] | During 2012, an investor relations advisor received warrants to purchase 30,000 shares of common stock at an exercise price of $1.77 per share exercisable at any time until April 19, 2014, for investor relations consulting services rendered in 2012. The expense recorded for the year ended December 31, 2012 was $10,000.
[3] | In connection with a private placement offering on November 10 and 30, 2011, warrants to purchase 2,144,656 shares of common stock at $1.67 per share were issued. All of the warrants are exercisable immediately and 1,857,156 warrants expire May 10, 2014 and 287,500 warrants expire May 30, 2014. In connection with a private placement offering on November 10 and 30, 2011, additional warrants to purchase 2,144,656 shares of common stock at $2.00 per share were issued. All of the warrants are exercisable immediately and 1,857,156 warrants expire November 10, 2016 and 287,500 warrants expire November 30, 2016. Also in connection with a private placement offering on November 10 and 30, 2011, placement agent warrants to purchase 18,447 shares of common stock at $1.67 per share were issued. Also in connection with a private placement offering on November 10 and 30, 2011, placement agent warrants to purchase 18,446 shares of common stock at $2.00 per share were issued. All the placement agent warrants are exercisable immediately and 18,447 warrants expire November 10, 2016 and 18,446 warrants expire November 30, 2016.
[4] | During 2011, an investor relations advisor received warrants to purchase 12,500 shares of common stock at an exercise price of $2.30 per share at any time until April 15, 2014, for investor relations consulting services rendered in 2011. The expense recorded for the year ended December 31, 2011 was $17,000.
[5] | In connection with a registered direct offering on December 14, 2010, warrants to purchase 930,664 shares of common stock at $3.06 per share were issued. All of the warrants are exercisable immediately and expire December 14, 2015.
[6] | In connection with a registered direct offering on January 26, 2010, warrants to purchase 1,041,432 shares of common stock at $3.00 per share were issued. All of the warrants are exercisable immediately and expire January 26, 2015. In addition, we issued warrants for placement agent fees to purchase 125,109 shares of our common stock at an exercise price of $3.75 per share. All of the warrants are exercisable immediately and expire January 26, 2015.
[7] | During 2010, an investor relations advisor received warrants to purchase 194,000 shares of common stock at an exercise price of $2.16 per share for investor relations consulting services rendered in 2010 and 2011. Our common stock did not reach a target price by February 28, 2011 and according to the agreement 134,000 warrants expired and no further expense was recorded.Warrants to purchase 60,000 shares of common stock are exercisable and outstanding at December 31, 2011 and expire October 1, 2013.
[8] | During 2010, an investor relations advisor received warrants to purchase 55,000 shares of common stock at an exercise price of $2.63 per share at any time until October 14, 2013, for investor relations consulting services rendered in 2010.
[9] | During 2010, an investor relations advisor received warrants to purchase 25,000 shares of common stock at an exercise price of $3.50 per share at any time until November 4, 2014, for investor relations consulting services rendered in 2010.
[10] | During 2009, a business consultant received warrants to purchase 150,000 shares of common stock at an exercise price of $2.07 per share at any time until July 23, 2014, for business consulting services rendered in 2009. 60,000 of the warrants were exercisable on December 31, 2011.The remaining 90,000 warrants expired July 23, 2010 because our stock did not reach specified trading prices.
[11] | In connection with the preferred stock offering in February 2008, warrants to purchase a total of 499,584 shares of common stock were issued. All of the warrants are exercisable immediately and expire February 24, 2014. The fair value of the warrants was $2.29 per share on the date of the grant using the Black-Scholes pricing model with the following assumptions: expected dividend yield 0.0%, risk-free interest rate 2.75%, expected volatility 110% and a term of 6 years.The exercise price of $3.50 was decreased to $3.00 after the January 2010 placement; to $2.55 after the December 2010 placement; to $1.45 after the November 2011 placement; and, to $0.50 after the October 2012 placement.
[12] | In connection with our acquisition of Somanta Pharmaceuticals, Inc. (Somanta) we exchanged for $1,576,000 due to Somanta vendors, for 538,508 shares of our common stock and warrants to purchase 246,753 shares of common stock at $3.50. The warrants expire January 4, 2014.
[13] | During 2008, an investor relations advisor received warrants to purchase 50,000 shares of common stock at an exercise price of $3.15 per share at any time until January 3, 2013, for investor relations consulting services rendered in 2008.
[14] | During 2008, an investor relations advisor received warrants to purchase 40,000 shares of common stock at an exercise price of $3.00 per share at any time until September 1, 2013, for investor relations consulting services. All of the warrants are exercisable.
[15] | In connection with the preferred stock offering in November 2007, warrants to purchase a total of 3,649,880 shares of common stock were issued. All of the warrants are exercisable immediately and expire six years from date of issue. The fair value of the warrants was $2.50 per share on the date of the grant using the Black-Scholes pricing model with the following assumptions: expected dividend yield 0.0%, risk-free interest rate 3.84%, expected volatility 114% and a term of 6 years.The exercise price of $3.50 was decreased to $3.00 after the January 2010 placement; to $2.55 after the December 2010 placement;to $1.45 after the November 2011 placement;and, to $0.50 after the October 2012 placement.
[16] | In connection with the convertible note offerings in 2006, warrants to purchase a total of 4,581,816 shares of common stock at $1.32 per share were issued. All of the warrants are exercisable immediately and expire six years from date of issue. On February 10, 2012 these warrants were extended an additional three years.

X
- Definition Fair value of warrants or rights on the date of grant using Black-Scholes pricing model. + References No definition available. + Details
Name: | accp_ClassOfWarrantsAndRightsFairValue
Namespace Prefix: | accp_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Class of warrants or rights issued during the period. + References No definition available. + Details
Name: | accp_ClassOfWarrantsOfRightsIssuedDuringPeriod
Namespace Prefix: | accp_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Expiration date of each class of warrants or rights outstanding. + References No definition available. + Details
Name: | accp_ClassOfWarrantsOrRightExpirationDate
Namespace Prefix: | accp_
Data Type: | xbrli:dateItemType
Balance Type: | na
Period Type: | instant

X
- Definition Exercisable period of warrants and rights outstanding. + References No definition available. + Details
Name: | accp_ClassOfWarrantsOrRightsExercisablePeriod
Namespace Prefix: | accp_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Expiration date of each class of warrants or rights outstanding. + References No definition available. + Details
Name: | accp_ClassOfWarrantsOrRightsExpirationDate
Namespace Prefix: | accp_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | instant

X
- Definition Extended period to exercise of warrants or rights outstanding. + References No definition available. + Details
Name: | accp_ClassOfWarrantsOrRightsExtendedExercisablePeriod
Namespace Prefix: | accp_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Aggregate number of warrants or rights expired during period. + References No definition available. + Details
Name: | accp_ClassOfWarrantsOrRightsWarrantsExpired
Namespace Prefix: | accp_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Decreased exercise price of warrants due to placement at various periods. + References No definition available. + Details
Name: | accp_DecreasedExercisePriceOfWarrants
Namespace Prefix: | accp_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Expense recognized during the period for investor relations consulting services. + References No definition available. + Details
Name: | accp_InvestorRelationsConsultingServicesExpense
Namespace Prefix: | accp_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Issuance warrants for placement agent fees, to purchase shares of common stock. + References No definition available. + Details
Name: | accp_IssuanceOfWarrantsForPlacementAgentFee
Namespace Prefix: | accp_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Gross proceeds before issuance cost from issuance of common stock and warrants. + References No definition available. + Details
Name: | accp_ProceedsFromIssuanceOfCommonStockAndWarrantsGross
Namespace Prefix: | accp_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The total cost of the acquired entity including the cash paid to shareholders of acquired entities, fair value of debt and equity securities issued to shareholders of acquired entities, the fair value of the liabilities assumed, and direct costs of the acquisition. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 141 -Paragraph 51 -Subparagraph d -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. + Details
Name: | us-gaap_BusinessAcquisitionCostOfAcquiredEntityPurchasePrice
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Number of shares of equity interests issued or issuable to acquire entity. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 141 -Paragraph 51 -Subparagraph d -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. + Details
Name: | us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition The exercise price of each class of warrants or rights outstanding. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(i)(4)) -URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph i -Subparagraph 4 -Article 4 + Details
Name: | us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
Namespace Prefix: | us-gaap_
Data Type: | us-types:perUnitItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | us-gaap_ClassOfWarrantOrRightLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The specified number of securities that each class of warrants or rights outstanding give the holder the right but not the obligation to purchase from the issuer at a specific price, on or before a certain date. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(i)(2)) -URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph i -Subparagraph 2 -Article 4 + Details
Name: | us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Aggregate amount of each class of warrants or rights outstanding. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 129 -Paragraph 4 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(i)) -URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph i -Article 4 + Details
Name: | us-gaap_ClassOfWarrantOrRightOutstanding
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueAssumptionsExpectedDividendRate
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueAssumptionsExpectedTerm
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueAssumptionsExpectedVolatilityRate
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Risk-free interest rate assumption used in valuing an instrument. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueAssumptionsRiskFreeInterestRate
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 19 -Subparagraph a -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 95 -Paragraph 18 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585 + Details
Name: | us-gaap_ProceedsFromIssuanceOrSaleOfEquity
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of new stock issued during the period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher AICPA -Name Accounting Principles Board Opinion (APB) -Number 12 -Paragraph 10 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration